🇺🇸 FDA
Patent

US 8592456

IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

granted A61PA61P1/00A61P1/04

Quick answer

US patent 8592456 (IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation) held by 4SC DISCOVERY GMBH expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
4SC DISCOVERY GMBH
Grant date
Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P1/00, A61P1/04, A61P1/14, A61P17/00